Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2018

Primary Completion Date

March 31, 2020

Study Completion Date

September 30, 2020

Conditions
Advanced or Metastatic Biliary Tract Cancer
Interventions
DRUG

Varlitinib

everyday

DRUG

Capecitabine

from Day 1 to Day 14 followed by 7-day of rest period, every 21 days.

Sponsors
All Listed Sponsors
lead

ASLAN Pharmaceuticals

OTHER

NCT03129074 - Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer | Biotech Hunter | Biotech Hunter